Growth Opportunities In Gene Editing Technologies, Advanced RNA Therapeutics, Antibody Drug Conjugates and Biomanufacturing 2022
03 Mar 2023
siRNA
DUBLIN, March 2, 2023 /PRNewswire/ -- The "Growth Opportunities In Gene Editing Technologies, Advanced RNA Therapeutics, Antibody Drug Conjugates and Biomanufacturing" report has been added to
ResearchAndMarkets.com's offering.
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) highlights some of the recent innovations in gene editing technologies, which aim to make them more targeted and efficient. It also covers few innovations around ADCs (antibody drug conjugates) and its different components which are paving the way for development of safer and longer acting ADCs. In addition, advances in RNA therapeutics including small activating RNA and circular RNA based therapeutics and targeted delivery carriers have been covered. A PoC diagnostic to diagnose psoriasis and automation platform for egg and embryo management are also a part of this issue.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Key Topics Covered:
Innovations in Gene Editing Technologies, Advanced RNA Therapeutics, Antibody Drug Conjugates and Biomanufacturing
Exploring the Potential of Circular Ribonucleic Acid (RNA) Therapeutics To Treat Rare Diseases
Value Proposition of ORNA Therapeutics
ORNA Therapeutics-Investor Dashboard
Accelerated Clinical Development of Small Active RNAs to Treat Difficult to Target Diseases
Value Proposition Mina Therapeutics
Mina Therapeutics-Investor Dashboard
Artificial Intelligence (AI)-based Platform Developing Biocompatible RNA Delivery System to Target Multiple Organs
Value Proposition of Sixfold Bioscience
Sixfold Bioscience-Investor Dashboard
Engineered Ribonucleoprotein (RNP) for Delivery of Gene Editing Molecule
Value Proposition of Spotlight Therapeutics
Spotlight Therapeutics-Investor Dashboard
Advanced Analytical Tools to for Cell Line Optimization and Development
Valitacell-Value Proposition
ValitaCell-Investor Dashboard
AI Powered, Integrated Supply Chain Management Platform for Cell and Gene Therapies
Trakcel's Proposition
Trakcel-Investor Dashboard
Novel Class of Site-Specific Nuclease for Development of Allogeneic CAR-T Cells
Value Proposition of Poseida Therapeutics
Poseida Therapeutics-Investor Dashboard
Synthetic Enzyme based on Meganucleases For Developing Innovative Therapies
Value Proposition of Precision Biosciences,
Precision Biosciences-Investor Dashboard
RNA Interference & TCR Inhibition technology for Generating Allogeneic CAR-T Cells
Value Proposition of Celyad Oncology
Celyad Oncology-Investor Dashboard
Targeted Gene-editing Technology Using Short Guide RNA for the Development of Transformative Medicines
Value Proposition of Editas Medicine
Editas Medicine-Investor Dashboard
Engineered Zinc Finger Nuclease Based Targeted Gene Editing
Sangamo Therapeutics-Value Proposition
Sangamo Therapeutics-Investor Dashboard
Therapeutics Targeting Growth Factor Pathways to Treat Fibrotic Indications
AgomAb Therapeutics-Value Proposition
AgomAb Therapeutics-Investor Dashboard
Dermagnostix GmbH-Value Proposition
Dermagnostix-Investor Dashboard
Toolbox Approach to Developing ADC Technologies for Various Types of Oncologic Targets
Iksuda Therapeutics' Value Proposition
Iksuda Therapeutics-Investor Dashboard
Plug-and-play Engineered Antibodies for Targeted Cancer and Viral Disease Therapeutics
Xencor's Value Proposition
Xencor-Investor Dashboard
Streamlined and Automated Cryospecimen Management Platform for Frozen Eggs and Embryos for Infertility Treatment
TMRW Life Sciences' Value Proposition
TMRW Life Sciences-Investor Dashboard
Digital Biomarkers for Drug Development Trials in the Pharmaceutical Industry
VivoSense's Value Proposition
VivoSense-Investor Dashboard
Flexible, Scalable and Cost-efficient Peptide Based Linker Platform, Offering Highly Stable Antibody Drug Conjugates
Value Proposition of Araris Biotech
Araris biotech-Investor Dashboard
Key Contacts
2. Appendix
Criteria for Rating of Innovations--Explanation
A selection of companies mentioned in this report includes
Dermagnostix
VivoSense
For more information about this report visit https://www.researchandmarkets.com/r/adr4w2
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.